Angelika Mühlebner Selected Research

Focal Cortical Dysplasia

6/2022	Unexpected Effect of IL-1β on the Function of GABAA Receptors in Pediatric Focal Cortical Dysplasia.
1/2022	Increased expression of complement components in tuberous sclerosis complex and focal cortical dysplasia type 2B brain lesions.
10/2021	Impaired myelin production due to an intrinsic failure of oligodendrocytes in mTORpathies.
10/2021	Balloon cells promote immune system activation in focal cortical dysplasia type 2b.
1/2021	Neurite Outgrowth Inhibitor (NogoA) Is Upregulated in White Matter Lesions of Complex Cortical Malformations.
1/2021	Upregulation of the pathogenic transcription factor SPI1/PU.1 in tuberous sclerosis complex and focal cortical dysplasia by oxidative stress.
12/2019	Changes in vascular density in resected tissue of 97 patients with mild malformation of cortical development, focal cortical dysplasia or TSC-related cortical tubers.
9/2019	Pathophysiology of neurodevelopmental mTOR pathway-associated epileptic conditions: Current status of biomedical research.
3/2019	Long-term seizure outcome after epilepsy surgery in patients with mild malformation of cortical development and focal cortical dysplasia.
1/2019	Cognitive functioning after epilepsy surgery in children with mild malformation of cortical development and focal cortical dysplasia.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Angelika Mühlebner Research Topics

Disease

21	Tuberous Sclerosis (Bourneville's Disease) 11/2022 - 01/2016
17	Epilepsy (Aura) 01/2022 - 11/2014
15	Focal Cortical Dysplasia 06/2022 - 02/2012
13	Seizures (Absence Seizure) 06/2022 - 11/2016
6	Drug Resistant Epilepsy 01/2022 - 02/2012
5	Astrocytoma (Pilocytic Astrocytoma) 11/2022 - 11/2017
5	Inborn Genetic Diseases (Disease, Hereditary) 01/2022 - 11/2016
4	Partial Epilepsies (Epilepsy, Partial) 06/2022 - 02/2012
3	Temporal Lobe Epilepsy 10/2021 - 03/2016
3	Hippocampal Sclerosis 10/2021 - 03/2016
3	Inflammation (Inflammations) 10/2021 - 01/2016
3	Malformations of Cortical Development 10/2021 - 11/2017
2	Brain Neoplasms (Brain Tumor) 11/2022 - 11/2017
2	Neuroinflammatory Diseases 06/2022 - 01/2019
2	Autism Spectrum Disorder 01/2022 - 10/2020
2	Intellectual Disability (Idiocy) 01/2022 - 01/2017
2	Status Epilepticus (Complex Partial Status Epilepticus) 10/2021 - 01/2018
2	Hamartoma 01/2020 - 01/2016
2	Carcinogenesis 01/2020 - 06/2018
2	Infantile Spasms (West Syndrome) 10/2019 - 01/2019
1	Spinal Muscular Atrophy (Progressive Muscular Atrophy) 01/2022
1	Neoplasms (Cancer) 01/2022
1	Neurologic Manifestations (Neurological Manifestations) 01/2022
1	Vaccinia 01/2022
1	Neurodevelopmental Disorders 10/2021
1	Congenital, Hereditary, and Neonatal Diseases and Abnormalities (Congenital Disorders) 01/2021
1	Cognitive Dysfunction 10/2020
1	Neurocutaneous Syndromes (Phakomatoses) 01/2020
1	Hydrocephalus (Hydrocephaly) 01/2020
1	Depressive Disorder (Melancholia) 01/2020
1	Hemimegalencephaly 01/2019
1	Encephalitis (Encephalitis, Rasmussen) 01/2019
1	Ganglioglioma 06/2018
1	Glioma (Gliomas) 06/2018
1	Glioblastoma (Glioblastoma Multiforme) 06/2018
1	Vomiting 01/2018
1	Ketosis 01/2018
1	Autistic Disorder (Autism) 01/2017
1	Nervous System Diseases (Neurological Disorders) 11/2016
1	Gliosis 01/2016
1	Myoclonic Epilepsies (Myoclonic Encephalopathy) 01/2015

Drug/Important Bio-Agent (IBA)

21	trans-sodium crocetinate (crocetin)IBA 11/2022 - 01/2016
8	Pharmaceutical PreparationsIBA 06/2022 - 02/2012
6	TOR Serine-Threonine KinasesIBA 01/2022 - 01/2016
4	Mechanistic Target of Rapamycin Complex 1IBA 10/2021 - 01/2016
4	mitomycin C-dextranIBA 10/2021 - 01/2019
3	Sirolimus (Rapamycin)FDA Link 11/2022 - 01/2017
3	Anticonvulsants (Antiepileptic Drugs)IBA 11/2017 - 01/2015
2	Complement System Proteins (Complement)IBA 01/2022 - 09/2019
2	AntioxidantsIBA 10/2021 - 01/2019
2	Proteins (Proteins, Gene)FDA Link 10/2020 - 01/2017
2	Adrenocorticotropic Hormone (ACTH)FDA Link 10/2019 - 01/2019
1	CytokinesIBA 06/2022
1	ChloridesIBA 06/2022
1	Reticulin (Reticular Fiber)IBA 01/2022
1	Everolimus FDA Link 01/2022
1	MTOR InhibitorsIBA 01/2022
1	Phosphotransferases (Kinase)IBA 01/2022
1	Cell Adhesion MoleculesIBA 01/2022
1	polycaprolactoneIBA 10/2021
1	IronIBA 10/2021
1	Transcription Factors (Transcription Factor)IBA 01/2021
1	RNA (Ribonucleic Acid)IBA 01/2021
1	Matrix Metalloproteinases (MMPs)IBA 01/2020
1	Glucocorticoid Receptors (Glucocorticoid Receptor)IBA 01/2020
1	MicroRNAs (MicroRNA)IBA 06/2018
1	3-Hydroxybutyric Acid (beta-Hydroxybutyric Acid)IBA 01/2018
1	Proteasome Endopeptidase Complex (Proteasome)IBA 01/2017
1	AMPA Receptors (AMPA Receptor)IBA 11/2016

Therapy/Procedure

3	Therapeutics 10/2021 - 02/2012
3	Ketogenic Diet 10/2019 - 01/2015
1	Enteral Nutrition (Feeding, Tube) 01/2018
1	Parenteral Nutrition 01/2018